Roche Announces Significant Overall Survival Benefit for Kadcyla in HER2-Positive Early-Stage Breast Cancer

TOKYO, December 11, 2023 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a press release regarding Kadcyla to extend overall survival in the KATHERINE Phase 3 clinical trial for HER2-positive early breast cancer on December 8. Please refer to the link below for details of the press release: Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment https://www.roche.com/media/releases/med-cor-2023-12-08b

The release as fetched from its publisher. chugai-pharm.co.jp ↗